This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cellceutix Reports Production Of Its Anti-Cancer Drug Kevetrin™ Has Begun

BEVERLY, Mass., March 14, 2011 /PRNewswire/ -- Cellceutix Corporation (OTCQB: CTIX) is pleased to announce that Kevetrin™, the Company's flagship compound for the potential treatment of cancers not responding to existing drugs (drug-resistant cancers), has begun production for clinical trials. This was confirmed by Formatech Inc.( Andover , MA) which formulates developmental medications for clinical trials.

"We appreciate being given the opportunity to develop and manufacture Kevetrin™, Cellceutix's first clinical candidate," said Indu Javeri, Ph.D., CEO of Formatech. "We have worked closely with Dr. Menon and his team at Cellceutix over the recent months and we look forward to encouraging results from their clinical trials. We understand that Kevetrin has a unique mechanism of action that could dramatically impact the treatment of multiple cancers. In an industry that produces very few truly novel products, it is refreshing to see a new potential chemotherapy compound like Kevetrin™."

Leo Ehrlich, CEO of Cellceutix, commented, "We are thrilled that the production process is underway.  I very much appreciate Dr. Javeri's comments."  Mr. Ehrlich continued, "Our lead compound Kevetrin™ is moving forward, and rapidly garnering attention.  People are now realizing the results and potential of our hard work.  Kevetrin™ has a unique chemical structure; the first in its class of chemistry to be used as an anti-cancer agent. Our preclinical testing results were beyond our best expectations against drug-resistant cancers. Most important of all was the discovery of the p53--Guardian angel--mechanism of action.  These factors are quite important as we move towards clinical trials.  Should we achieve proper efficacy during the planned clinical trials, we hope that the FDA may grant Accelerated Approval or Priority Review for Kevetrin™.  While there are no assurances of success in biotechnology research, at Cellceutix we are enthusiastic about what has been achieved thus far, and believe the best is yet to come."

Accelerated Approval or Priority Review programs by the FDA programs were put into effect approximately twenty years ago specifically for new drugs that provide the best opportunity for a viable therapy in an area of unmet medical need. In these cases, it is to the advantage of all involved to get these compounds to late-stage clinical trials quickly, without sacrificing any safety.  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.21 -0.44%
FB $117.80 -0.22%
GOOG $701.26 0.80%
TSLA $211.34 -5.00%
YHOO $36.94 2.60%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs